Featured News

Patients Who Have Participated In a Celiac Disease Clinical Trial Needed for 2021 Patient Education & Advocacy Summit.

A new intensive study confirms that people with celiac disease are frequently exposed to gluten in food.

On November 14 and 15, more than 2,500 supporters from 48 states and seven countries laced up to move 3.1 miles (5K) “across the country” for a cure at the CDF Virtual Turkey Trot. This monumental event raised more than $184,000 for celiac disease research.

The Celiac Disease Foundation’s article, “How Nonprofits Can Make Their Virtual Fundraisers a Success” was featured in the Digestive Health and Wellness section of their website.

A new Alcohol and Tobacco Tax and Trade Bureau (TTB) ruling released October 13 allows a gluten-free label on spirits distilled from gluten-containing grains.

One of our most important research investments over the last several years has been in iCureCeliac®, the nation’s celiac disease patient registry. This month, researchers published three important studies that used iCureCeliac® as the data source.

Researchers from Takeda Pharmaceuticals and the Celiac Disease Foundation presented a study which concluded that despite gluten-free diet adherence, many patients with celiac disease still have symptoms that substantially impact their lives.

A study led by Columbia University and Celiac Disease Foundation researchers examined probiotic use among celiac disease patients and was an Outstanding Poster Presenter recipient at the 2020 ACG Annual Scientific Meeting.

The following study, which examines the prevalence of dermatitis herpetiformis (DH), was made possible by the Foundation’s iCureCeliac® patient registry.

New research from Columbia University revealed differences in the antibodies present, adding evidence that NCGS involves a different kind of inflammation in the gut in response to gluten.